Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study

He, Jianming; Schmerold, Luke; Rampelbergh, Rian Van; Qiu, Lugui; Potluri, Ravi; Dasgupta, Anandaroop; Li, Lin; Li, Yunan; Hu, Peter; Nemat, Sepideh; Smugar, Steven S.; Zeltzer, Paul M.; Appiani, Carlos; Li, Qing; Mehra, Maneesha; Richarz, Ute

doi:10.1007/s12325-020-01546-0

Cited by 8 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the prevalence of t (11;14) in this analysis (14% for patients in the first-line setting with results recorded) was similar to the general prevalence reported in ECOG trials and the IFM clinical trials (~16%) [15,29]. In addition, patient demographics in this study are comparable with those reported for other US realworld studies, including International Oncology Network (ION) electronic medical record data [30], Surveillance, Epidemiology and End Results (SEER) Medicare data [31], and the Optum database [32]. Median age at diagnosis in the current study was 69 years compared with 69 and 71 years in the ION [30] and Optum databases [32], respectively.…”

Section: Discussionsupporting

confidence: 83%

“…In addition, patient demographics in this study are comparable with those reported for other US realworld studies, including International Oncology Network (ION) electronic medical record data [30], Surveillance, Epidemiology and End Results (SEER) Medicare data [31], and the Optum database [32]. Median age at diagnosis in the current study was 69 years compared with 69 and 71 years in the ION [30] and Optum databases [32], respectively. A higher representation of non-White patients was included in this study: 64% of patients in the current study were White versus 52% from the ION report [30].…”

Section: Discussionsupporting

confidence: 73%

See 1 more Smart Citation

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

Atrash

Flahavan

et al. 2022

Blood Cancer J.

View full text Add to dashboard Cite

A clearer understanding of the prognostic implications of t(11;14) in multiple myeloma (MM) is needed to inform current and future therapeutic options. We utilized real-world data from a US database to examine treatment patterns and outcomes in patients by t(11;14) status compared with high- and standard-risk subgroups across different lines of therapy (LoT). This retrospective, observational cohort study used de-identified patient-level information from adults with MM and first-line treatment initiation between January 2011 and January 2020, followed until February 2020. The high-risk cohort comprised patients with high-risk genetic abnormalities per mSMART criteria (including those with co-occurring t(11;14)). Among 6138 eligible patients, 6137, 3160, and 1654 received first-, second-, and third-line treatments, respectively. Of 645 patients who had t(11;14), 69.1% had t(11;14) alone, while 30.9% had co-occurring high-risk abnormalities. Altogether, 1624 and 2544 patients were classified as high- and standard-risk, respectively. In the absence of biomarker-driven therapy, treatment patterns remain similar across LoT in high-risk, t(11;14)+, and standard-risk subgroups. Across all LoT, patient outcomes in the high-risk subgroup were less favorable than those in the t(11;14)+ and standard-risk subgroups. Thus, there is an opportunity for novel therapeutics targeted to t(11;14) and other defined subgroups to personalize MM therapy and optimize patient outcomes.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 73%

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

Atrash

Flahavan

et al. 2022

Blood Cancer J.

View full text Add to dashboard Cite

show abstract

“…This study demonstrated that MM frontline therapies in China are distinct from US and Western countries. The thalidomide-containing regimen is the most common frontline treatment in all the MM patients enrolled in the study, while Bortezomib-containing and lenalidomide regimens are the primary frontline treatment among MM patients from US and Western countries in the same period ( Fonseca et al, 2020 ; He et al, 2021 ; Kumar et al, 2021 ; Atrash et al, 2022 ). It may be partly attributed to the economic factor and the availability of new agents.…”

Section: Discussionmentioning

confidence: 99%

“…I (Fonseca et al, 2020;He et al, 2021;Kumar et al, 2021;Atrash et al, 2022). It may be partly attributed to the economic factor and the availability of new agents.…”

Section: Iss Stagementioning

confidence: 99%

“…Over the past decades, the treatment pattern of MM in China has significantly changed with the availability of more novel agents ( Huang et al, 2017 ; Cai et al, 2022 ). However, the treatment regimens during the same period are clinically distinct between China and European countries and the United States countries in real-world practice due to the later launch and medical insurance coverage of new agents in China ( Qian et al, 2018 ; Fonseca et al, 2020 ; He et al, 2020 ; He et al, 2021 ; Atrash et al, 2022 ). Therefore, the attrition rates of LOTs may vary due to the different frontline treatment patterns in China.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China

Tang

Yang²,

Li³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: For multiple myeloma (MM), the proportions of patients reaching the subsequent line of therapy (LOT) decline gradually and real-world data describing the attrition rates of LOT in Chinese MM were limited. Herein, we investigated the attrition rates by subsequent LOTs and their relevant risk factors in MM patients in China.Methods: MM patients who had been hospitalized and received at least one LOT from January 2008 to August 2019 in West China Hospital Sichuan University were retrospectively recruited. Demographic and clinical characteristic data were obtained from the “HemaTank” Chinese Multiple Myeloma Database. The Cox proportional hazards regression model was applied to analyze the risk factors of frontline treatment attrition.Results: A total of 1,255 newly diagnosed MM were enrolled, with 573 (45.7%) patients receiving only one LOT and 682 (54.3%) patients receiving more than one LOT. Thalidomide with dexamethasone/prednisone was the most common frontline treatment before 2017, while bortezomib-based regimens constituted the majority of frontline treatment in 2017 and beyond. The attrition rates from the first to the fifth LOT exhibited a gradual upward trend (45.7%, 48.7%, 58.9% and 62.5%, respectively). Meanwhile, 54.3%, 27.9%, 11.5%, and 4.3% of all the enrolled MM patients received a second, third, fourth and fifth LOT. MM who underwent autologous stem cell transplantation (ASCT) showed lower attrition rates across all LOTs (range 12%–56.8%) than MM without ASCT (range 49.1%–64.5%). The multivariate Cox regression model revealed that ISS stage III (HR 2.07, p < .001), elevated LDH (HR 1.47, p = .006), and comorbidities such as amyloidosis (HR 1.63, p = 0 .01), hepatic disease (HR 1.36, p = .022), pulmonary disease (HR 1.38, p = .022), and cardiac disease (HR 1.62, p = .004) were independent risk factors for MM patients attritted from the frontline treatment.Conclusion: In this study, the attrition rates were generally high and increased gradually across all LOTs. Nearly half of MM patients received only one LOT, and higher tumor burden and more comorbidities may be associated with fewer subsequent LOTs. The high attrition rates highlight the importance of applying the most optimal frontline treatment regimen rather than salvaging subsequent LOTs.

show abstract

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States

Fonseca,

Chinaeke,

Gupta-Werner

et al. 2023

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study

Cited by 8 publications

References 28 publications

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States

Contact Info

Product

Resources

About